News

Sarepta initiated with a bullish view at Wells Fargo on Elevidys
Sarepta Therapeutics (NASDAQ:SRPT) stock draws an Overweight rating at Wells Fargo, based on commercial prospects for ...
Sarepta price target lowered to $182 from $196 at Morgan Stanley
Morgan Stanley analyst Michael Ulz lowered the firm’s price target on Sarepta (SRPT) to $182 from $196 and keeps an Overweight rating on the ...
Sarepta Therapeutics (SRPT) Receives a Buy from Morgan Stanley
Morgan Stanley analyst Michael Ulz maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...
Sarepta initiated with an Overweight at Wells Fargo
Wells Fargo initiated coverage of Sarepta (SRPT) with an Overweight rating and $115 price target Despite the recent Gr5 AE case, the firm ...